• Tuesday, April 25, 2023 @ 7:00 am

Some major achievements of Swiss biotech innovation…

  • 1998 Monoclonal antibodies Trastuzumab
    Herceptin, Roche, breast cancer
  • 1998 Interferon beta-1a
    Rebif, Serono, multiple sclerosis
  • 2001 Bosentan
    Tracleer, Actelion, pulmonary arterial hypertension (PAH)
  • 2003 Kinase inhibitors Imatinib
    Gleevec, Novartis, cancer
  • 2013 CRISPR-Cas9 gene editing
    CRISPR Therapeutics using technology to treat genetic diseases
  • 2013 Humanized anti-CD20 monoclonal antibody Obinutuzumab
    Gazyva, Glycart/Roche, chronic lymphocytic leukaemia
  • 2017 CAR-T cell therapy Tisagenlecleucel
    Kymriah, Novartis, leukaemia
  • 2019 Humanized single chain antibody anti-VEGF Brolucizumab
    Beovu, Esbatech/Novartis, wet-AMD
  • 2019 Gene therapy Onasemnogene abeparvovec-xioi
    Zolgensma, Novartis, paediatric spinal muscular atrophy (SMA)
  • 2021 Aducanumab
    Aduhelm, Neuroimmune/Biogen, Alzheimer’s disease
  • 2023 DDM Genomics and Multimodal platform
    SOPHiA GENETICS hits milestone of One Million Genomic Profiles analyzed by the SOPHiA DDM™ platform

Most of these highlights were achieved in international collaboration and benefit patients around the world. They do not represent a comprehensive list but rather a selection that emphasizes the diversity of modalities that have been developed over time and the broad range of medical needs they help to address.

You may also be interested in